This tool is for research exploration only. It is not a medical device and does not provide medical advice. Drug candidates, evidence scores, and AI-generated content are not clinical recommendations. Always consult your medical team before making any treatment decisions.

Drug Candidates

5 candidates mapped to SDH-deficient disease pathways

All (50)established (7)clinical trial (8)preclinical (13)theoretical (22)
Sunitinib

Sutent

established

Multi-kinase inhibitor (VEGFR/PDGFR/KIT)

Vegf SignalingMtor Pi3k Akt
GISTPPGL/PCCRCC
Evidence Score
78
FDA Approved1 trial
Regorafenib

Stivarga

established

Multi-kinase inhibitor (VEGFR/KIT/PDGFR/FGFR/RAF)

Vegf SignalingMtor Pi3k AktFgfr Signaling
GISTRCC
Evidence Score
60
FDA Approved1 trial
Everolimus

Afinitor

clinical trial

mTOR inhibitor (rapalog)

Mtor Pi3k Akt
All SDH tumors
Evidence Score
58
FDA Approved1 trial
Metformin

Glucophage

preclinical

Biguanide / AMPK activator

Mtor Pi3k AktOxidative Stress Ros
All SDH tumors
Evidence Score
40
FDA Approved
Capivasertib

Truqap

theoretical

Pan-AKT inhibitor (allosteric PH-domain binding; AKT1/2/3)

Mtor Pi3k Akt
PPGL/PCCGISTRCC
Evidence Score
32
FDA Approved1 trial